Understanding Peptide Half-Lives: Why Timing Matters

Half-life is one of the most practically important pharmacokinetic concepts for anyone designing a peptide protocol, and one of the most frequently misapplied. Understanding half-life correctly is not merely academic - it directly determines how often you need to dose, when you need to dose relative to your goals, and what plasma concentration profile you are actually producing versus what you intend.

What Is Half-Life?

A compound's half-life (t1/2) is the time required for its plasma concentration to fall to 50% of its peak value. This is a property of how rapidly the body eliminates the compound - through enzymatic degradation, renal clearance, hepatic metabolism, or combinations thereof.

For peptides specifically, the primary elimination mechanism is proteolytic degradation - the same enzymes (proteases, peptidases) that digest dietary protein will also break down exogenous peptides. This is why most peptides have relatively short half-lives and why route of administration matters significantly: oral bioavailability is low for most peptides because they are largely degraded in the GI tract before reaching systemic circulation.

Why Timing Matters

Knowing a compound's half-life allows you to:

• Set the correct dosing frequency - Dosing a compound with a 2-hour half-life once daily produces a very different (and generally suboptimal) plasma concentration curve versus dosing it 3 times daily
• Achieve steady-state concentration - After approximately 4-5 half-lives of consistent dosing, plasma concentration reaches a stable plateau; understanding this informs when you should start expecting effects
• Time specific physiological windows - For GH-axis peptides, dosing must align with endogenous GH pulsatility to amplify rather than disrupt natural rhythms
• Plan washout periods - When cycling off a compound, knowing the half-life tells you when it has been substantially cleared (after ~5 half-lives, 97% of the compound has been eliminated)

Half-Life Reference Table

Peptide	Approximate Half-Life	Dosing Implication	Notes
BPC-157	~4 hours (SubQ)	1-2x daily dosing	Morning + evening most common
TB-500 (TB4 Frag)	~72 hours	Weekly or twice-weekly	2 mg twice/week in loading; weekly in maintenance
Ipamorelin	~2 hours	2-3x daily or before sleep	Short half-life; pulse timing critical
CJC-1295 (no DAC)	~30 minutes	2-3x daily, timed carefully	Mimics natural GHRH pulse
CJC-1295 (with DAC)	~8 days	Once or twice weekly	DAC = Drug Affinity Complex; binds albumin for sustained release
Semaglutide	~7 days	Once weekly	Designed for weekly dosing; FDA-approved schedule
Tirzepatide	~5 days	Once weekly	Effective 7-day dosing despite ~5 day t1/2
GHK-Cu	Variable (~minutes systemic; topically depot-dependent)	Daily for SubQ; daily-twice daily topical	Copper complexation affects clearance
Kisspeptin-10	~30-60 minutes	Pulsatile dosing 2-3x daily	LH pulse timing critical for T optimization
PT-141 (Bremelanotide)	~2-3 hours	As needed, 45 min pre-activity	FDA approved; onset ~45 min, duration ~6-12 hrs

Steady-State Concentration

When you dose a compound repeatedly before the previous dose has fully cleared, concentrations accumulate until input equals output - this plateau is called steady state. It takes approximately 4-5 half-lives to reach steady state regardless of dosing frequency.

Practical examples:

• Ipamorelin (t1/2 ~2 hrs): Reaches steady state after ~10 hours of consistent dosing
• CJC-1295 DAC (t1/2 ~8 days): Takes 32-40 days of weekly injections to reach steady state - meaning effects may not be fully apparent until week 5-6
• Semaglutide (t1/2 ~7 days): Steady state at ~4-5 weeks; this is why weight loss effects build gradually over the first month

Pulsatile vs. Continuous Exposure

For GH-axis peptides, there is a critical distinction between pulsatile and continuous receptor stimulation. Growth hormone secretion is naturally pulsatile - large bursts occur primarily during deep sleep and after fasting or exercise. Continuous receptor stimulation (as produced by a very long-acting GHRH analog without careful timing) can lead to receptor desensitization and reduced net GH output over time.

This is why:

• CJC-1295 without DAC (short half-life, pulse-mimetic) is often preferred over CJC-1295 with DAC for GH pulse preservation
• Ipamorelin is typically dosed before sleep to align with the largest natural GH pulse
• Many practitioners cycle GH-axis peptides to prevent receptor downregulation

Practical Timing Protocols

Applying half-life knowledge to real protocols:

• BPC-157 for injury: Dose in the morning and approximately 8 hours later. Proximity to the injury site (SubQ injection near affected area) may matter more than strict timing.
• Ipamorelin + CJC-1295 (no DAC): Dose together 30 minutes before sleep on an empty stomach. Both have short half-lives and will produce a pulse that aligns with sleep-phase GH secretion.
• TB-500 loading phase: Twice-weekly injection (e.g., Monday and Thursday) during loading; the 72-hour half-life means you maintain meaningful plasma levels throughout the week.
• Semaglutide: Once weekly on a consistent day. No intra-day timing requirement due to 7-day half-life.